Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...

GEN uncovers seven biopharma-related trends based on interviews with experts and other industry stakeholders, as well as ...

Dyson cordless vacuums are arguably some of the best that you can get to clean your house; the only issue is that they are ...

Whether or not you need RGB lighting in your power supply, the GameMax RGB-Smart 1050 Pro PSU delivers solid, reliable performance at an affordable price.

A dedicated Women in Tech Week event, coffee roulette, and boosting knowledge, confidence and connections – the women in tech ...

To welcome 2025, here’s a round-up of what to look forward to in and out of the country we call home.

The drug and biotech industry had a tough time in the past couple of months after Trump announced the appointment of Robert F ...

New Year’s Walmart deals include markdowns across fashion, home, kitchen, tech, and more and includes discounts up to 89 ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. Investors need to pay close ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

Numerous ASX resources stocks delivered gains despite a tough market cycle. Here's a collection of the top winners and ...